ENANTA PHARMACEUTICALS INC Segments Disclosure
16. Segment Information
The Company manages its operations as a operating segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is on discovering and developing small molecule drugs with an emphasis on virology and immunology. The Company’s Chief Operating Decision Maker (“CODM”) is the Company’s (“CEO”). The CODM reviews consolidated operating results and utilizes net loss from the Statement of Operations against budget forecasts as the primary measure of segment profit or loss in making decisions surrounding allocating resources and assessing performance of the Company. The CODM is regularly provided detailed expense information, including expenses by expense category and program. The CODM makes decisions surrounding capital and personnel allocation using this information on a consolidated basis. Asset information on a reportable segment basis is not disclosed as this information is not separately identified and internally reported to the Company’s CODM. The CODM is regularly provided information on total cash, which is inclusive of cash, cash equivalents and short-term marketable securities, as a measure of segment assets. As of September 30, 2025, the Company’s cash, cash equivalents and short-term marketable securities were $188,864. The following table presents selected financial information with respect to the Company’s single operating segment for the years ended September 30, 2025, 2024 and 2023 (in thousands):
|
|
Years Ended September 30, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Revenue |
|
|
|
|
|
|
|
|
|
|||
Royalty revenue |
|
$ |
65,324 |
|
|
$ |
67,635 |
|
|
$ |
78,204 |
|
License revenue |
|
|
— |
|
|
|
— |
|
|
|
1,000 |
|
Total revenue |
|
|
65,324 |
|
|
|
67,635 |
|
|
|
79,204 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|||
RSV |
|
|
59,808 |
|
|
|
86,367 |
|
|
|
78,120 |
|
COVID-19 |
|
|
587 |
|
|
|
4,625 |
|
|
|
66,082 |
|
HBV |
|
|
152 |
|
|
|
371 |
|
|
|
6,974 |
|
Total virology |
|
|
60,547 |
|
|
|
91,363 |
|
|
|
151,176 |
|
KIT |
|
|
18,052 |
|
|
|
19,822 |
|
|
|
— |
|
STAT6 |
|
|
16,614 |
|
|
|
4,691 |
|
|
|
— |
|
Total immunology |
|
|
34,666 |
|
|
|
24,513 |
|
|
|
— |
|
Early discovery |
|
|
11,328 |
|
|
|
14,995 |
|
|
|
8,253 |
|
Other programs for out-licensing |
|
|
199 |
|
|
|
605 |
|
|
|
4,095 |
|
Total other programs |
|
|
11,527 |
|
|
|
15,600 |
|
|
|
12,348 |
|
General and administrative |
|
|
43,933 |
|
|
|
57,850 |
|
|
|
52,887 |
|
Loss from operations |
|
|
(85,349 |
) |
|
|
(121,691 |
) |
|
|
(137,207 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|||
Interest expense |
|
|
(7,681 |
) |
|
|
(10,940 |
) |
|
|
(5,148 |
) |
Interest and investment income, net |
|
|
9,442 |
|
|
|
14,770 |
|
|
|
11,360 |
|
Change in fair value of Series 1 nonconvertible preferred stock |
|
|
39 |
|
|
|
73 |
|
|
|
— |
|
Total other income, net |
|
|
1,800 |
|
|
|
3,903 |
|
|
|
6,212 |
|
Loss before income taxes |
|
|
(83,549 |
) |
|
|
(117,788 |
) |
|
|
(130,995 |
) |
Income tax benefit (expense) |
|
|
1,660 |
|
|
|
1,743 |
|
|
|
(2,821 |
) |
Net loss |
|
$ |
(81,889 |
) |
|
$ |
(116,045 |
) |
|
$ |
(133,816 |
) |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.